A Study on limb sparing surgery on extremity soft tissue sarcoma. by Marimuthu, S
A Dissertation on 
 
A STUDY ON LIMB SPARING SURGERY ON EXTREMITY SOFT 
TISSUE SARCOMA 
 
 
 
 
 
 
Submitted to 
The Tamilnadu Dr.M.G.R.Medical University 
in partial fulfillment of the requirement 
for the award of degree of 
 
 
 
 
M.Ch. (SURGICAL ONCOLOGY) 
 
BRANCH VII 
 
 
 
 
 
 
 
 
 
KILPAUK MEDICAL COLLEGE 
THE TAMILNADU Dr.M.G.R.MEDICAL UNIVERSITY 
CHENNAI, TAMILNADU 
 
 
AUGUST 2008 
BONAFIDE CERTIFICATE 
 
Certified that the dissertation titled “A STUDY ON LIMB SPARING 
SURGERY ON EXTREMITY SOFT TISSUE SARCOMA”  is a  
bonafide work of the Candidate Dr.S.MARIMUTHU, carried under my supervision. 
Certified further that to the best of my knowledge the work reported herein does not 
form part of any other thesis or dissertation on the basis of which a degree or award 
was conferred on an earlier occasion on this or any other candidate. 
 
 
 
 
Prof. M.Dhanapal M.D.,D.M.   Prof.R.Rajaraman, M.S., M.Ch., 
Dean        Prof. & Head  
Kilpauk Medical College    Department of Surgical Oncology 
Chennai.      Govt. Royapettah Hospital, Chennai. 
 
 
 
 
 
 
ACKNOWLEDGEMENT 
 
 I wish to acknowledge my indebtedness to all those who have been helpful in 
compiling this dissertation. 
 It is my pleasure and privilege to record my deep sense of gratitude to  
Prof. Dr. R. Rajaraman M.S., M.Ch., Professor & Head, Department of Surgical 
Oncology, Government Royapettah Hospital, Kilpauk Medical College, Chennai, for 
his constant encouragement, motivation and guidance given to me in bringing forth 
this piece of work. 
 I am extremely grateful to Dr. S. Jegadesh Chandra Bose M.S., M.Ch, 
Assistant Professor of our Department for his constant support, valuable comments 
and suggestions in every phase of the study.   
 Special gratitude is due to the other Assistant Professors of our  
Department, Dr. M.P.Viswanathan M.S., M.Ch., Dr.S. Balasubramanian M.S., 
MCh., and Dr. S.Subbiah M.S., M.Ch.,for their help and kindness rendered. 
 I shall be failing in my duty if I do not thank my fellow Post graduates and 
Technical staff and Para Medical staff for their generous assistance throughout this 
study. 
 Last but not least, I would like to pay my gratitude to all those cancer patients 
who despite their illness were very cooperative to make this study possible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONTENTS 
 
 
 
1. INTRODUCTION 
 
 
2. AIM OF STUDY 
 
 
3. REVIEW OF LITERATURE 
 
 
4. MATERIALS AND METHODS 
 
 
5. OBSERVATION AND ANALYSIS 
 
6. CONCLUSIONS 
 
 
7. BIBLIOGRAPHY 
 
 
8. APPENDIX 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
STUDY ON LIMB SPARING SURGERY IN EXTREMITY 
 
 SOFT TISSUE SARCOMA 
 
 
                                                     1. INTRODUCTION 
         
 
     Soft tissue sarcomas are the most frequent sarcomas.  They are a rare and heterogeneous 
group of tumors that arise from the supporting extra skeletal tissues (i.e., muscle, fascia, 
nerve, connective, fibrous, and fatty tissues. Although soft tissues comprise 75% of the 
average body weight, these neoplasms represent less than 1% of all adult and 15% of 
pediatric malignancies. Soft tissue sarcomas are a disease of adulthood, occurring most 
commonly in persons between 30 and 60 years of age. The sole exception is 
rhabdomyosarcoma, which occurs in young children. 
 
        Each of the various soft tissue sarcomas has a unique morphology, biological behavior, 
and prognosis. However, like bone sarcomas, they all share certain biological and behavioral 
characteristics. The clinical, radiographic, and surgical management of most soft tissue 
sarcomas is identical, regardless of histogenesis. 
     
      The treatment of soft tissue sarcoma has become multidisciplinary, as advances in 
biology, imaging, surgery, chemotherapy and radiotherapy have improved the outlook for 
these patients who have these malignancies. 
 
      Before 1970s, the standard treatment for any primary soft-tissue sarcomas of the 
extremities was amputation of the affected arm or leg. Since then, better understanding of 
the biological behavior of these tumors and advances in surgical technique,  bioengineering, 
radiographic imaging, radiotherapy, and chemotherapy have led to the advent  of limb-
sparing surgery.  
    
     Limb-sparing surgery is now a safe and effective method of treatment for many, if not 
most, individuals. The goal of limb-sparing surgery is safe and complete removal of the 
tumor with preservation of limb function. 
 
     Limb-sparing surgery is now the standard of care for bone and soft tissue sarcomas of the 
extremities and is performed in approximately 90% of all cases.   All patients must be 
considered and evaluated for limb-sparing surgery, and the decision to proceed with an 
amputation should be made on a case-by-case basis. Such decisions are based on local 
anatomic considerations, tumor grade and stage, and consideration of the functional and 
psychological impact of the procedure. 
 
 
 
 
 
 
 
 
 
 2. AIM OF STUDY 
  
1. To study the incidence of soft tissue sarcoma in our institution. 
2. To study the rate of limb sparing surgery and amputations  
3. To study age distribution and sex incidence. 
4. To study the presentations of soft tissue sarcoma on diagnosis. 
5. To study stage of the disease at presentation. 
6. To study the incidence of various pathological types. 
7. To study the surgical management, reconstruction techniques, complications and their 
management 
8. To study the functional outcome after limb sparing surgery.  
9. To study the oncological outcome after limb sparing surgery. 
 
 
 
 
 
 
 
 
 
 
 
 3. REVIEW OF LITERATURE 
History 
      The word sarcoma dates to Galen  and the Greek term describing a fleshy growth. The 
idea of a sarcoma as a distinct type of cancer was not formalized until the mid 1800s by 
Virchow. 
 
      The first successful hemipelvectomy was reported by Cherles Girard, in 1895, for a 
recurrent osteosarcoma. Over the next several decades, hemipelvectomy (also known as 
interpelvic, interilioabdominal, interinominoabdominal, interiliosacropubic, transiliac, or 
hindquarter amputation) became the standard surgical treatment for sarcomas of the proximal 
lower extremity, inguinal region, buttock, and musculoskeletal hemi pelvis. 
 
       The first successful forequarter amputation was performed by Grosby, in 1836, for 
osteosarcoma. 
 
      Without challenge, the most radical of all potential sarcoma surgeries is the translumbar 
amputation or hemicorporectomy. First postulated by Kredel, in 1950 ( as the “halfectomy”), 
but not successfully performed until 1961 by Aust and Absolon. This rare procedure has been 
reserved for extensive but isolated benign and malignant processes involving the pelvis, 
including skeletal and soft tissue tumors. 
 
       Beginning as early as the 1930s, the necessity of amputation in all cases of soft tissue 
sarcoma began to be questioned. In 1958, Bowden and Booher published a classic paper on 
the fundamental shift in the principles and techniques of sarcoma surgery. In a series of 36 
patients treated with limb sparing muscle group wide excision, their local recurrence rate was 
a very reasonable 16%. 
 
         These ideas did not mature into the modern concept of multimodality limb conservation 
until the 1980s. One of the seminal studies to solidify the potential equivalence of limb 
conservation to amputation was performed by Rosenberg at the national cancer institute from 
1975 to 1981. Based upon the results from his study and other studies, a National Institute of 
health Consensus Development Conference in 1984 on “Limb-Sparing treatment of Adult 
Soft Tissue Sarcomas” concluded that there is clearly a role for limb-sparing surgery, often 
by combining surgery with radiation or chemotherapy. 
 
        From this point forward, the emphasis on the treatment of soft tissue sarcomas shifted 
from extensive amputations to limb preservation strategies, post resection functionality and 
quality of life. 
 
      The modern radical resection and reconstructive approaches are mainly contributed by 
major developments in micro vascular plastic surgical techniques, an increased emphasis on 
functionality, the development of prosthetic materials, neurovascular reconstruction, down 
staging with isolated limb perfusion, and the concept of limb remodeling and replantation. 
 
     As a consequence, although amputation was once considered the standard of care for 
extremity sarcomas, “amputation free survival” has become an important clinical outcome in 
the treatment of this disease. 
     . 
Incidence 
       Soft tissue sarcoma represents less than 1% of all adult and 15% of pediatric 
malignancies. Incidence of soft tissue sarcoma is more than bone sarcoma with ratio of 3:1. 
Incidence is more in male than female (Ratio - 4:1). It is rarer than benign soft tissue tumors 
with ratio of 1:100.  
 
       Soft tissue sarcomas are a disease of adulthood, occurring most commonly in persons 
between 30 and 60 years of age. The sole exception is rhabdomyosarcoma, which occurs in 
young children. 
 
Distribution 
     Soft tissue sarcoma can occur in any site throughout the body. Forty three percent are in 
extremities with two thirds of extremity lesions occurring in the lower limb, and 34% are 
intra-abdominal, divided between visceral (19%) and retroperitoneal (15%) lesions. Trunk 
sarcoma occurs in 10% of individuals and others in 10% of patients. 
 
Etiology 
        Most soft tissue sarcomas have no clearly defined cause, although multiple associated or 
predisposing factors have been identified. 
        Various genetic syndrome  which are predisposing to soft tissue sarcoma are 
neurofibromatosis type 1, retinoblastoma, LI-Fraumeni syndrome, Gardner’s syndrome, 
Werner’s syndrome, Goblin’s syndrome, Carney’s triad and tuberous sclerosis. 
 
       Radiation therapy is the known cause of soft tissue sarcoma. They are most often seen in 
diseases that are commonly treated with radiotherapy and in those in which a long survival 
period is expected. The prime candidate diseases are breast cancer, lymphoma, and cervical 
cancer. The children are at risk due to time latency involved. It arises close to penumbra of 
radiotherapy fields. 
 
     Most common tumors following radiotherapy are osteosarcoma followed by Malignant 
Fibrous Histiocytoma, angiosarcoma or lymphangiosarcoma. Usually the tumor is high grade. 
 
     Lymphedema has long been established as a factor in the development of 
lymphangiosarcoma. The most well recognized association is with the post mastectomy, post 
irradiated lymphadematous arm, described by Stewart and Treves. This is not radiation 
induced sarcoma  
 
     Human herpes virus 8 is cause of  Kaposi’s sarcoma. Epstein-Barr virus is implicated in 
soft tissue sarcoma in immune compromised people. Chemicals implicated in etiology are 
Phenoxy acetic acid, Vinyl chloride, Thorotrast, arsenic. 
       The issue of trauma as a predisposing factor is more controversial. Often a minor episode 
of injury is the factor that draws attention to the presence of a mass. 
 
Classification 
 It is based on line of differentiation  i.e. the type of tissue formed rather than from the 
type of origin. WHO’s classification is used widely. 
• Fibrous tumors 
• Fibrohistiocytic tumors 
• Lipomatous tumors 
• Smooth muscle tumors 
• Skeletal muscle tumors 
• Tumors of Blood vessels & lymphatics 
• Perivascular tumors 
• Synovial tumors 
• Mesothelial tumors 
• Peripheral N. sheath tumors 
• Primitive neuroectodermal tumors(PNET) 
• Extra skeletal osseous & cartilagenous tumors 
• Miscellaneous tumors 
 
The basis cell appearance on smears, they are classified clinically as follows 
• Myxoid tumors 
• Spindle cell tumors 
• Pleomorphic tumors 
• Polygonal tumors 
• Round cell tumors 
• Miscellaneous 
 
Pathology  
      The three most common histopathologic subtypes are MFH, liposarcoma, and 
leiomyosarcoma. Histopathologic type is anatomic site dependent. The common subtypes in 
the extremities are liposarcoma, MFH, synovial sarcoma and fibrosarcoma. Synovial sarcoma 
is common in hand and foot. In the skin,  Kaposi’s sarcoma in common. 
 
     Soft tissue sarcoma is differentiated from benign soft tissue tumors from its aggressive 
growth, invasive and destructive potential, occurrence of metastases and high rate local 
recurrence if not treated adequately. 
 
Grading of sarcoma 
        After establishing the diagnosis of sarcoma, the most critical piece of information the 
pathologist can provide to the clinician is histologic grade. This remains the most important 
prognostic factor for determining disease-free and overall survival rate. 
 
        The pathologic features that define grade include cellularity, differentiation, 
pleomorphism, necrosis, and number of mitoses. 
 
      Unfortunately, the criteria for grading are neither specific nor standardized. Several 
grading scales and systems are used: a four-grade system (Broder’s), a three-grade system 
(low, intermediate, high) such as National Cancer Instituite (NCI) grading system and that of 
the French Federation of Cancer Centers Sarcoma group, and a binary system (low, high) as 
is used at Memorial Hospital. 
 
      Many pathologists consider mitotic activity and degree of necrosis to be the most 
important pathologic features. To define a practical grading system, the European 
Organization for Research and treatment of cancer (EORTC) conducted a study in which, the 
multivariate analysis showed only mitotic count (fewer than 3, 3 to 20, and more than 20 
mitoses per 10 consecutive high-power fields), the presence or absence of necrosis, and 
tumor size predicted survival. 
 
        Biologic markers such as mutation of p53, nuclear over expression of p53, and a high 
Ki-67 proliferation index are associated with high grade and poor survival, but not a 
independent indicators of prognosis and cannot at present be used to grade sarcomas 
 
       Several tumors that are considered sarcomas have no recognizable normal tissue 
counterpart ( e.g., alveolar soft part tumor, Ewing’s sarcoma, Epithelioid sarcoma). These 
tumors often have unique clinical features and usually are not graded.  
 
        In 2002 AJCC/TNM staging system of sarcoma, only two grades, low versus high are 
used to stage soft tissue sarcomas. To accurately determine tumor grade, an adequate tissue 
sample must be well fixed, well stained, and reviewed by an experienced sarcoma 
pathologist. 
 
Staging 
       Staging has an important role in determining the most effective treatment of soft tissue 
sarcomas. The stage is determined by the size of the tumor, the histologic grade, and whether 
it has spread to lymph nodes or distant sites. Intracompartmental or extra compartmental 
extension of extremity sarcomas is also important for surgical decision making. For complete 
staging, a thorough physical examination, x-rays, laboratory studies, and careful review of all 
biopsy specimens (including those from the primary tumor, lymph nodes, or other suspicious 
lesions) are essential. Computed tomographic scan of the chest is recommended for sarcomas 
larger than 5 cm (T2) or with moderate to poor differentiation (grades 2–4). Nodal 
involvement is rare, occurring in other less than 3% of patients with sarcoma  
     The staging system applies to all soft tissue sarcomas except Kaposi’s sarcoma, 
dermatofibrosarcoma, infantile fibrosarcoma, and angiosarcoma. In addition, sarcomas 
arising within the confines of the dura mater, including the brain, and sarcomas arising in 
parenchymatous organs and from hollow viscera are not optimally staged by this system. 
  
     Data to support this staging system are based on current analyses from multiple 
institutions and represent the recommendations of an AJCC task force on soft tissue sarcoma. 
In the era of cytoreductive neoadjuvant treatments, clinical and pathologic staging may be 
altered in the future. Because pathologic staging drives adjuvant therapy decisions, patients 
should be restaged after neoadjuvant therapies have been administered. 
 
       Histologic type, grade, and tumor size and depth are essential for staging. Histologic 
grade of sarcoma is one of the most important parameters of the staging system. Grade is 
based on analysis of various pathologic features of a tumor, such as histologic subtype, 
degree of differentiation, mitotic activity, and necrosis. Accurate grading requires an 
adequate sample of well-fixed tissue for evaluation. Accurate grading is not always possible 
on the basis of needle biopsies or in tumors that have been previously irradiated or treated 
with chemotherapy. 
 
       The current staging system does not take into account anatomic site. However, anatomic 
site is known to influence outcome, and therefore outcome data should be reported specifying 
site. Generic grouping of site is accepted. The following site groups can be used in reports 
that include sarcomas arising in tissues other than soft tissues (such as parenchymal organs). 
Extremity and superficial trunk can be combined; viscera, including all the intra-abdominal 
viscera, can also be combined. Where enough numbers exist, these can be reported by 
subdivision into the various components of the gastrointestinal tract. Lung, gastrointestinal, 
genitourinary, and gynecologic sarcomas should be grouped separately. 
 
 
Site Groups for Soft Tissue Sarcomas 
Head and neck 
Extremity and superficial trunk 
Gastrointestinal 
Genitourinary 
Visceral 
Retroperitoneal 
Gynecologic 
Breast 
Lung, pleura, mediastinum 
 
Inclusions 
       The present staging system applies to soft tissue sarcomas. Primary sarcomas can arise 
from a variety of soft tissues. These tissues include fibrous connective tissue, fat, smooth or 
striated muscle, vascular tissue, peripheral neural tissue, and visceral tissue. 
 
Regional Lymph Nodes 
      Involvement of regional lymph nodes by soft tissue sarcomas is uncommon in adults. 
When present, regional nodal disease has prognostic significance similar to that of visceral 
metastatic disease. 
 
  
Metastatic Sites 
      Metastatic sites for soft tissue sarcoma are often dependent on the original site of the 
primary lesion. For example, the most common site of metastatic disease for patients with 
extremity sarcomas is the lung, whereas retroperitoneal and gastrointestinal sarcomas often 
have liver as the first site of metastasis. 
     TNM / The American Joint Committee on Cancer (AJCC)  has designated staging by the 
four criteria of tumor size, nodal status, grade, and metastasis (TNGM).  
 
Grade and TNM Definitions  
Tumor grade (G)  
• GX: Grade cannot be assessed  
• G1: Well differentiated  
• G2: Moderately differentiated  
• G3: Poorly differentiated  
• G4: Poorly differentiated or undifferentiated  
Primary tumor (T)  
• TX: Primary tumor cannot be assessed  
• T0: No evidence of primary tumor  
• T1: Tumor 5 cm or less in greatest dimension  
o T1a: Superficial tumor  
o T1b: Deep tumor  
• T2: Tumor 5 cm or larger in greatest dimension  
o T2a: Superficial tumor  
o T2b: Deep tumor  
 Regional lymph nodes (N)  
• NX: Regional lymph nodes cannot be assessed  
• N0: No regional lymph node metastasis  
• N1: Regional lymph node metastasis  [Note: Presence of positive nodes (N1) is 
considered stage IV.]  
Distant metastasis (M)  
• MX: Distant metastasis cannot be assessed  
• M0: No distant metastasis  
• M1: Distant metastasis  
NOTES 
1. Superficial tumor is located exclusively above the superficial fascia without invasion 
of the fascia; deep tumor is located either exclusively beneath the superficial fascia, 
superficial to the fascia with invasion of or through the fascia, or both superficial yet beneath 
the fascia. Retroperitoneal, mediastinal, and pelvic sarcomas are classified as deep tumors. 
2. Ewing’s sarcoma is classified as G4. 
STAGE GROUPING 
 
IA      T1a       N0   NX   M0   G1–2     G1           Low 
           T1b      N0   NX   M0   G1–2     G1           Low 
IB       T2a      N0   NX   M0   G1–2     G1           Low 
           T2b      N0   NX   M0   G1–2     G1           Low 
IIA     T1a       N0   NX   M0   G3–4     G2–3       High 
           T1b      N0   NX   M0   G3–4     G2–3       High 
IIB      T2a      N0   NX   M0   G3–4     G2–3       High 
III       T2b      N0   NX   M0   G3–4     G2–3       High 
IV       Any T   N1           M0    Any G   Any G     High or Low 
           Any T  Any N        M1   Any G   Any G    High or Low 
     
Evaluation and Workup 
 
        All patients should be managed by a multidisciplinary team with expertise in soft-tissue 
sarcoma. The differential diagnosis of soft tissue sarcomas of the extremities includes ruling 
out desmoids, as well as the other malignant and benign lesions previously discussed. An 
essential element of the workup is a history and physical examination (H&P).  
 
        Laboratory tests have a limited role. Adequate and high-quality imaging studies are 
crucial to good clinical management of patients, because the presence of metastatic disease 
may change the management of the primary lesion and the overall approach to the patient’s 
disease management. Imaging studies should also provide details about tumor size and 
contiguity to nearby visceral structures and neurovascular landmarks.  
  
         Magnetic resonance imaging (MRI) with or without computed tomography (CT) is 
indicated for all lesions with a reasonable chance of being malignant. MRI is preferred for 
extremity sarcomas, whereas CT is preferred for retroperitoneal sarcomas. Plain radiograph 
of the primary lesion is optional. CT scan is done to image the primary if there is suspicion of 
involvement of bone. 
 
      Given the risk for hematogenous spread from soft tissue sarcoma to the lungs, imaging of 
the chest is essential for accurate staging. Abdominal/pelvic CT should be considered for 
myxoid liposarcoma, leiomyosarcoma, epithelioid sarcoma or angiosarcoma. 
 
         18Fluorodeoxyglucose-positron emission tomography (18FDG-PET) scan may be 
useful for prognostication, grading and to assess response to chemotherapy. Tumor 
metabolism data acquired by FDG-PET will be useful in accurate grading and 
prognostication in sarcoma. Recent reports in literature have demonstrated the value of 
FDG-PET scan in evaluating response to neoadjuvant chemotherapy in patients with high-
grade extremity soft tissue sarcomas, prediction of outcome in liposarcoma. 
 
       A large prospective study is underway to study the value of FDG-PET scan combined 
with CT scan in predicting disease-free survival in patients receiving neoadjuvant 
chemotherapy for soft tissue sarcoma 
 
BIOPSY 
      Biopsy is a key step in the diagnosis of soft-tissue tumors. An inadequately performed 
biopsy may fail to allow proper diagnosis, have a negative impact on survival, and ultimately 
necessitate an amputation to accomplish adequate margins of resection. 
       
    In a book published in 1958, Jaffe stated that a biopsy should be regarded as the final 
diagnostic procedure, not as a mere short cut to diagnosis. Biopsy must be preceded by 
careful clinical evaluation and analysis of the imaging studies. The diagnosis of a 
musculoskeletal lesion is based on these three parameters; all three have to fit and the 
diagnosis must be questioned when they do not match. 
         
      In the past, biopsies were performed routinely through a large incision with significant 
contamination of the surrounding soft tissues with tumor cells. The contamination, however, 
had minimal significance because most malignant tumors of the extremities and pelvis were 
treated with amputation.  
        
     Today, limb sparing procedures are performed in 90–95% of patients with 
musculoskeletal tumors of the extremities, and indications and surgical technique of 
musculoskeletal biopsy had to be changed to allow these procedures to be performed. 
 
Biopsy Considerations 
     Biopsy of a musculoskeletal lesion should be performed only at the conclusion of staging, 
which is the process that entails performing the imaging studies required to determine the 
characteristics and local extent of the tumor and the presence of metastatic disease. 
  
Anatomic Location of the Biopsy Tract 
 The guidelines can be summarized as follows:  
 
1. Decide, before biopsy, what part of the lesion is most representative of the underlying 
disease and will need to have a biopsy.   
2. Position  the point of entry along the planned incision of the definitive surgery.  
3. The biopsy tract must be the shortest way to the lesion; however, it must not violate 
4. more than one compartment and must be as remote as possible from the main 
neurovascular bundle of the extremity 
 
Biopsy Technique 
    After adequate planning of the biopsy tract, biopsy should be executed according to the 
following guidelines. 
1. Use the smallest longitudinal incision that is compatible with obtaining an adequate 
specimen. Transverse incisions are contraindicated because they require a wider soft-
tissue resection at the time of definitive surgery   
2. Use a knife or curette to avoid crushing or distorting the specimen’s texture  
3. Obtain enough tissue. Always send a specimen for frozen section or touch-prep to 
verify the presence of representative tumor material in the specimen. For needle 
biopsies, cytopathologic evaluation has to confirm the presence of viable tumor cells. If 
pathologic evaluation is negative or questionable, repeat the biopsy.   
4. As a general rule, culture what you biopsy and biopsy what you culture.  
5. Use meticulous hemostasis. Any hematoma around a tumor should be considered 
contaminated  
6. Use drains if necessary. The port of entry has to be in proximity and continuation with 
the skin incision, not to its sides. The drain path is considered contaminated and has to 
be excised with the surgical specimen. 
 
Types of biopsy 
      In soft tissue sarcoma, core needle biopsy, incisional biopsy and excision biopsy are used 
depending upon the situations. In most of the situation, Core needle biopsies are adequate and 
therefore recommended. In rare circumstances. Incisional biopsy is required. In tumors 
smaller than 5 cm, with superficial location excisional biopsy is the preferred approach. 
 
 
 
 
 
 
Figure. The smallest longitudinal incision that allows an adequate specimen to be 
obtained should be used. A transverse biopsy incision requires a wider resection of 
soft tissues at the time of the definitive surgery. 
  
Value of Tru-Cut Biopsy 
      In general, the important issue is the adequacy of the sample. Sufficient viable tissue is 
required that is both representative of the lesion and available for histopathologic evaluation, 
immunohistochemistry, and, when necessary, electron microscopy. As molecular markers 
become a factor in diagnosis, meticulous attention to the adequacy of biopsy, tissue 
preservation, and evaluation will be paramount.  
 
      Histopathologic interpretation varies from center to center and may be a major variable in 
decision making. As with other relatively rare lesions, it is essential that review of the 
histopathologic findings be made by an experienced group. More recent studies show 
improved diagnostic accuracy and confluence of opinion, at least for malignancy and grade. 
 
Fine-Needle Aspiration Cytology 
        Fine-needle aspiration (FNA) cytology has been examined by a number of authors. 
Some authors have argued that biopsy itself is not justified if FNA is available.  But it is 
usually confined to the confirmation of recurrence rather than used for the primary diagnosis. 
Figure.  A drain has to be positioned in 
proximity to and along the site for 
planned incision of the definitive 
procedure.  
      The use of FNA in patients with large sarcomas who are candidates for neoadjuvant 
therapy to improve survival is also problematic due to difficulty in grading and subtyping 
these tumors accurately from such small samples.  
 
Frozen Section 
 
      In some institutions, frozen section is relied on as the diagnostic tool of choice. For 
diagnosis of malignancy, frozen section is accurate, but for histopathologic subtypes and 
grade, it is inferior to permanent sections of either Tru-Cut or incisional biopsy. 
 
      Frozen section can guide retrieval of adequate diagnostic material and, depending on the 
initial evaluation, can be an important triage mechanism to direct further pathologic workup. 
However, open biopsy with the help of frozen-sectioning support may be indicated when the 
Trucut biopsy result is equivocal or for other clinical reasons.  
 
        Fatty lesions are not suitable for frozen-section evaluation, because of a loss of 
diagnostic material during frozen sectioning and other technical difficulties. In addition, 
freezing compromises the final interpretation on permanent sections. 
 
      Important application of frozen section is assessment of margin of resection. Negative 
margins of resection can be obtained by using this technique intraoperatively. 
 
Immunohistochemistry 
      As an ancillary technique, immunohistochemistry is an invaluable tool that provides 
excellent information in assisting the surgical pathologist in establishing a precise diagnosis, 
as well as providing relevant prognostic and therapeutic information. 
       
      One of its major utilities is to correctly identify a tumor as being of mesenchymal or 
nonmesenchymal origin. Once mesenchymal origin has been established, histologic 
subtyping according to specific cell lineage may be achieved with the use of lineage-specific 
markers. Tumors of uncertain cell lineage and tumors with primitive small round cell 
morphology are often characterized by a unique immunohistochemical phenotype. In this 
group of tumors, immunohistochemistry is most widely applied and is of greatest value. By 
diagnosing the small round cell tumors with aid of immunohistochemistry, line of 
management is differed from spindle cell soft tissue tumors. 
 
       Despite the rapid development of molecular genetic techniques, immunohistochemistry 
still remains the most important diagnostic tool in the diagnosis of soft tissue tumors aside 
from recognition of morphologic features and clinical correlation. 
 
Surgery  
      Although surgery remains the principal therapeutic modality, the extent of surgery 
required, along with the optimum combination of radiotherapy and chemotherapy, remains 
controversial. 
 
     Limb sparing operations are possible in at least 90% of patients. Wide en bloc resection is 
used most often, aiming to obtain a 2 cm margin of uninvolved tissue in all directions. The 
limiting factor is usually neurovascular or, occasionally, bony juxtaposition. Because most 
soft tissue sarcomas tend not to invade bone directly, only rarely does bone need to be 
resected. Soft tissue sarcomas uncommonly involve the skin, so major skin resection should 
be limited. 
 
      In situations of primary or recurrent tumors in which skin is involved, or which the tumor 
is so extensive that skin is involved, then consideration of free flap or rotational flap closure 
becomes important, particularly in those patients who are candidates for subsequent adjuvant 
radiation therapy. 
 
Amputation for Extremity Sarcoma 
 
    The most extensive resection is clearly amputation. This is only rarely indicated nowadays. 
The amputation should be reserved for tumors not able to be resected by any other means, 
without evidence of metastatic disease and the potential for good long-term functional 
rehabilitation. This includes patients with considerable cosmetic and functional deformity, 
who can be rendered symptom free by a major amputation. 
        
       Amputation should be considered for patient preference or if the tumor has the following 
characteristics: extensive soft tissue mass and/or skin involvement, major arterial or nerve 
involvement, extensive bony involvement that requires whole bone resection, failure of 
preoperative therapy or recurrence following prior adjuvant radiation. 
 
      The issue of amputation versus limb sparing surgery has been addressed by a prospective 
randomized trial at the NCI. Although local recurrence is greater in those undergoing limb 
sparing operation plus radiation than in those undergoing amputation, disease free survival is 
not different. 
 
Local recurrence 
       Local recurrence can occur after a limb sparing surgery. Follow up data confirms that 
salvage is almost invariably possible, but there is no impact in long term survival.   
 
CLASSIFICATION OF SURGICAL PROCEDURES 
     There are four basic types of excisions (see the figure). Each is based on the relationship 
of the dissection plane to the tumor and its pseudocapsule.  
      
      An intralesional excision is performed within the tumor mass and results in removal of 
only a portion of it; the pseudocapsule and macroscopic tumors are left behind.  
      
     In a marginal excision, the dissection plane passes through the pseudocapsule of the 
tumor. Such a resection may leave microscopic disease.  
 
     Wide (en-bloc) excision entails removal of the tumor, its pseudocapsule, and a cuff of 
normal tissue peripheral to the tumor in all directions. This is the desired margin for sarcoma 
resection; however, the adequate thickness of the normal tissue cuff is a matter of 
controversy. For both soft-tissue and bone sarcomas, it is generally believed to be a few 
centimeters. 
  
         
 
 
            Radical excision involves removal of the tumor and the entire anatomical 
compartment within which it is located. Traditionally it is mentioned as the fourth excision 
type. It excludes the possibility of skip metastases. In compartmental resections, fascia and 
periosteum are accepted as wide margin. 
              
Figure. Various excision types for soft-tissue sarcoma. 
      An amputation is not necessarily an adequate cancer operation, but it is a method of 
achieving a specific margin. It may entail a marginal, wide, or radical excision, depending 
upon the plane in which it passes. Staging studies are used to assess local tumor extent and 
relevant local anatomy, and thereby determine how a desired surgical margin may be 
achieved. 
 
RADIATION THERAPY 
Preoperative RT 
 
      The usual dose of preoperative RT is 50 Gy. An intraoperative boost or a postoperative 
boost with brachytherapy or an external-beam RT is recommended for positive or close 
margins. Preoperative RT has several advantages. First, the treatment volume is smaller, 
because the need to cover the operative field is not present. Second, preoperative radiation 
may reduce seeding during surgical manipulation of the tumor. The tumor may or may not 
regress with preoperative RT, but the pseudocapsule may thicken and become acellular, 
easing resection and decreasing the risk of recurrence. However, the main disadvantage of 
preoperative RT is its effect on wound healing. A higher complication rate has been observed 
when primary closure is used. Therefore, involvement of a plastic surgeon in the team may be 
necessary to reduce wound complications when preoperative radiation is contemplated. After 
preoperative radiation, 3-6 weeks interval before resection is necessary to decrease the risk of 
wound complications. Very long intervals between resection and postoperative radiation are 
not recommended. 
         If wide margins are obtained, additional radiation may not be needed. Often, margins 
are close because of the proximity of many of these tumors to major neurovascular bundles or 
bone. At the time of resection, surgical clips should outline the area of recurrence risk. 
Brachytherapy boosts should be delivered several days after surgery, through catheters placed 
at operation, with doses of 12-20 Gy based on margin status. Alternatively, a single 
intraoperative dose to the tumor bed of 10-16 Gy, based on margin status, can be delivered 
immediately after resection with exposure of the area at risk, avoiding uninvolved organs. 
External-beam RT boosts may be an alternative to brachytherapy or intraoperative radiation: 
recommended doses are 10-14 Gy for close margins, 16-20 Gy for microscopically positive 
margins, and 20-26 Gy for grossly positive margins. Many institutions are no longer giving a 
boost after preoperative radiation to patients who have widely negative margins, based on 
local control rates that 
approach 95% with preoperative radiation at 50 Gy and negative margins. 
 
Postoperative RT 
        Postoperative RT has been to improve local control in patients with high-grade 
extremity soft tissue sarcomas with positive surgical margins. When surgical resection is the 
initial therapy, postoperative RT choices include intraoperative radiation therapy (IORT), 
brachytherapy or external beam RT. RT is not a substitute for suboptimal surgical resection, 
and re-resection may be necessary. If the patient has not previously received RT, one could 
attempt to control microscopic residual disease with postoperative RT if re-resection is not 
feasible. 
 
        External-beam RT is delivered to large fields after surgical healing is complete (at 3-8 
weeks) to doses of 50 Gy. Most institutions include the entire operative bed within that 
radiation field. Total doses of RT should always be determined by normal tissue tolerance. 
For intraabdominal or retroperitoneal tumors, this dose may be decreased to 45 Gy. An 
intraoperative boost may not be possible if radiation morbidity is high. 
        If no intraoperative radiation or brachytherapy was used in the immediate operative or 
postoperative period, an external-beam RT boost should be added. For negative margins, an 
additional 10-16 Gy is recommended to a reduced field that includes the original tumor bed, 
based on grade and width of margins. For microscopically positive margins, an additional 16-
20 Gy is recommended; for grossly positive margins, an additional 20-26 Gy is suggested. 
 
       Brachytherapy alone has been used as an adjuvant in patients with negative margins. 45-
50 Gy to the tumor bed has been shown to reduce recurrence without a significant effect on 
wound healing. However, brachytherapy-alone techniques require special expertise and 
significant experience. If brachytherapy is used as a boost, doses of 10-20 Gy based on 
margin are recommended; a boost dose of 10-16 Gy for close margins or 20 Gy for positive 
margins is recommended. 
 
     Recent reports from a retrospective study suggest that IORT provides excellent local 
control to soft tissue sarcoma of the extremity, when used as a boost to external beam RT.   
 
TREATMENT 
Low Grade Tumors (Stage I) 
 
       Surgery is the primary treatment for stage I (T1a-1b, N0, M0) low-grade tumors and is 
considered definitive if margins are greater than 1 cm or the fascia plane is intact. 
Postoperative RT is considered when final margins are 1 cm or less (category 2B). Surgical 
resection alone or in combination with RT (category 1) is recommended for stage I (T2a-b, 
N0, M0) low-grade tumors. RT may not be necessary in patients with small lesions (5 cm or 
less), because these tumors are less frequently associated with local recurrence. 
  
          There are data from two randomized trials and three large single-institution studies that 
support using adjunctive RT in appropriately selected patients. Patients receiving either 
preoperative or postoperative RT have similar rates of local control and progression-free 
survival. However, preoperative RT is associated with a greater incidence of wound 
complications, especially in lower extremity tumors. Therefore, the risk of local recurrence 
versus the toxicity of adjuvant RT should be assessed before making a decision regarding 
radiation. 
 
High-Grade Tumors (Stage II or III) 
 
         Large high-grade extremity sarcomas (greater than 10 cm) at high risk for local 
recurrences and metastases and should be considered for preoperative therapy.  Preoperative 
chemotherapy or chemoradiation is used in many centers for high-grade tumors to downstage 
a large tumor to enable effective surgical resection, especially in the case of chemo sensitive 
histologies. Concurrent chemoradiation with doxorubicin-based regimens has been shown to 
improve local control rates in patients with soft tissue sarcoma. Available evidence although 
underpowered, suggests that anthracycline-based postoperative chemotherapy would improve 
disease-free survival in selected patients who are at high risk of recurrence but otherwise are 
in good performance status. 
 
         Sarcoma Meta Analysis Corporation performed a meta-analysis of 14 randomized trials 
(1,568 patients) which compared adjuvant chemotherapy to follow-up and in some cases 
radiation therapy after surgery with a variety of sarcomas. The result of the meta-analysis 
showed that doxorubicin-based chemotherapy prolongs relapse-free survival in adults with 
localized, resectable soft tissue sarcoma of the extremity and was associated with decreased 
recurrence rates. However, adjuvant chemotherapy does not appear to improve overall 
survival. Another recent analysis of 674 patients with stage III soft tissue sarcoma (1984-
1999) revealed that clinical benefits from doxorubicin-based chemotherapy lasted for less 
than a year. In an Italian randomized cooperative trial, patients with high-grade or recurrent 
extremity sarcoma were randomized to receive postoperative chemotherapy with epirubicin 
and ifosfamide or observation alone. After 
a median follow-up of 59 months, median disease-free survival (48 months vs.16 months) 
and median overall survival (75 months vs. 46 months) were significantly better in the 
treatment group. 
 
       Remarkably little data have been generated in the adjuvant setting regarding the 
combination of aggressively dosed ifosfamide plus doxorubicin supported by hematopoietic 
cytokine therapy. Phase III randomized study (EORTC-62931) is ongoing to assess the 
efficacy of adjuvant chemotherapy after definitive surgery in patients with 
high-grade primary or recurrent soft tissue sarcoma at any site. Interim overall survival data 
are encouraging from an ongoing phase III trial (EORTC-62961) of regional hyperthermia 
versus chemotherapy (etoposide, ifosfamide, adriamycin) alone for patients with high-risk 
soft tissue sarcomas, especially for extremity sarcomas. 
 
       Treatment options for stage II or III high-grade tumors should be decided by a 
multidisciplinary team, based on the performance status, comorbid factors including age, 
location and histologic subtype of the tumor and institutional experience. Surgery followed 
by RT with or without chemotherapy is the primary treatment for resectable high-grade 
sarcomas. The NCCN guidelines recommend various neoadjuvant approaches including 
preoperative RT or chemotherapy or chemoradiation prior to surgery, followed by 
postoperative radiation with or without chemotherapy for respectable tumors with acceptable 
functional outcomes and for potentially resectable tumors with concerns for adverse 
functional outcomes. Adjuvant chemotherapy alone can be considered in the case of patients 
who have received preoperative radiation alone. Surgery alone is an option for small tumors 
that can be resected with wider surgical margins. 
 
 
 
Recurrent Disease 
           The management of recurrent disease or primary presentation with metastases  
encompasses a heterogeneous group of patients and clinical scenarios. For a patient with a 
local recurrence, treatment decisions should be made using the same algorithm as for patients 
with a new primary lesion. . 
 
Surveillance 
       Surveillance is deemed important to detect recurrences that might still be potentially 
curable. However, very limited data is available in the literature on effective surveillance 
strategies. The guidelines outline a prudent follow-up schedule that avoids excessive testing. 
Higher grade and larger tumors have a higher risk of dissemination; therefore, the 
surveillance recommendations for patients with these tumors are somewhat more intensive, 
particularly for the first 3 years after resection. Periodic imaging (MRI, CT, or consider 
ultrasound) of the primary site should be done based on the estimated risk of loco regional 
recurrence. However, in situations where the area is easily followed by physical examination, 
imaging may not be required. After 10 years, the likelihood of developing a recurrence is 
small and follow-up should be individualized. 
 
        Stage I tumors are routinely followed with H&P every 3 to 6 months for 2 to 3 years and 
then annually.  Baseline imaging should be considered after primary therapy. Chest x-ray 
should also be considered every 6 to 12 months. For stage II and stage III tumors, H&P and 
chest imaging (plain radiograph or chest CT) should be done every 3 to 6 months for 2-3 
years, then every 6 months for the next 2 years, and then annually.        Because these 
patients’ risk never returns to zero, long-term follow-up is indicated, including consideration 
of MRI or CT scanning.80 Chest imaging (plain radiograph or chest CT) is performed every 
3 to 6 months for 5 years and then annually, given the risk of metastatic disease in these high-
grade lesions. There has never been a study to prove that the use of more sensitive CT scans 
in routine surveillance would improve clinical outcomes. According to the reported data from 
M. D. Anderson Cancer Center, routine use of chest CT adds little clinical benefit, when risk 
of pulmonary metastases is low.81 However, in certain subsets of patients in whom chest 
radiographs are difficult to interpret because of anatomic considerations (scarring, 
emphysema, etc), chest CT surveillance may be indicated. 
 
REHABILITATION AFTER LIMB-SPARING SURGERY 
     Although limb-sparing surgery  can enhance the quality of life it does cause a variety of 
functional impairments, and creates a need for early intensive rehabilitative intervention. 
 
       Rush defined medical rehabilitation as “maximal preservation of physical, psychological, 
social, occupational, creative and economical function in conjunction to malignant disease 
and its treatment”. 
 
      For many years it has been assumed that investing in extensive rehabilitation efforts for 
patients with poor prognoses and short life expectancies could not be justified from an 
economic perspective. Now that cure rates among patients who have undergone Limb 
Sparing Surgery are 60–80%, this assumption is clearly no longer correct. It is no less 
important to rehabilitate patients with metastatic disease.  
 
  LIMB SPARING SURGERY versus AMPUTATION 
      Limb Sparing Surgery  can result in survival rates and disease-free periods that equal 
those achieved with amputation. The presumed functional and psychological advantages of 
Limb Sparing surgery over amputation, however, have yet to be established. Limb Sparing 
Surgery appears to offer the possibility of better psychological functioning and an intact body 
image, but it is more complex and demanding than amputation and is associated with more 
morbidity. The duration of surgery is longer, and infection, pain, and other postoperative 
complications are more common.  
 
      Otis et al. compared energy cost during gait in osteosarcoma patients after resection of 
the distal femur and knee joint and replacement with an endoprosthesis with that of patients 
who had undergone an above-knee amputation. The former had a lower energy cost during 
gait than the latter. 
        
       Eiser et al. noted that one of the disadvantages of Limb Sparing Surgery is that additional 
hospitalizations may be necessary in the case of complications  
 
       It is important to emphasize that, in order to justify Limb Sparing Surgery, the procedure 
must provide limb function equal or superior to that provided by an external prosthesis after 
amputation. At the same time the tumor must be resected according to principles of oncologic 
surgery (i.e. there must be free margins and minimal damage to major neurovascular bundles 
and muscles). Despite the disadvantages, nearly all patients believe that an attempt to salvage 
a limb is worth the time and effort. 
 
  
 
 
 
 
 
 
 
       
             4. MATERIALS AND METHODS 
        
       Patients admitted and undergone limb sparing surgery for extremity soft tissue sarcoma 
between January 2004 to April 2008 in the Department of Surgical Oncology, Government 
Royapettah Hospital, Chennai were taken for study. 
  
        Data were collected  in all patients. Patient’s age and sex were noted. Histories like 
presence of swelling, its duration, presence of pain and its duration, other symptoms and 
family history were recorded. Previous history of surgery, biopsy if any and treatment were 
taken. 
 
         Physical examination was done to note site, size of swelling and presence or absence of 
metastases. Previous surgical scar, its length, present status, orientation to longitudinal axis of 
limb were noted. 
 
       All patients were evaluated with X-ray chest and CT Scan local part or MRI of local part. 
CT Scan chest was done in all cases. Histology was obtained with trucut biopsy. If there was 
already biopsy, it was reviewed.   
    
      Patients with metastatic disease were excluded from study. Suitable patients for limb 
salvage were undergone surgery. Those patients requiring amputation were excluded.         
Postoperative complications and its management were observed. Histopathology, grade, and 
margin status were noted. Histopathology is compared with previous reports. Surgical, 
functional and oncological outcome are evaluated. 
 
     Patients were followed up regularly once a month in first year, every two months in 
second month, every three months in third year, every 6 months in fourth and fifth year and 
then annually. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. OBSERVATION AND ANALYSIS 
       
       Musculoskeletal sarcomas consisted of 2.24% of all cancers admitted from January 2004 
to April 2008. Soft tissue sarcoma represents less than 1% of all adult of all malignancies  in 
various studies but in this series it represented about 1.64%. 
 
Cancers Number Percentage 
Musculoskeletal sarcomas 292 2.24 
Other cancers 12719 97.76 
Total 13011 100 
 
Cancers Number Percentage 
              Soft tissue sarcomas 213 1.64 
Other cancers 12798 98.34 
Total 13011 100 
 
        Soft tissue sarcomas consisted of 73% (213 cases) of total 292 cases (bone sarcoma-
22%[63] , fibromatosis- 5%[16] of cases] with ratio of soft tissue sarcoma to bone sarcoma 
3.5:1 compared to 3:1 in the literature. 
 
 
MUSCULOSKETAL SARCOMAS NUMBER % 
SOFT TISSUE SARCOMAS 213 73 
FIBROMATOSIS 16 5 
 BONE SARCOMAS  63 22 
TOTAL 292 100 
 
         Extremity soft tissue sarcomas consisted of 57% (122 cases) of total 213 soft tissue 
sarcoma cases (0ther sites-43% [91] of cases). 
 
Site distribution of soft tissue sarcoma Frequency  Percentage  
Extremity 122 57 
Other sites 91 43 
Total 213 100 
 
       Admission in Memorial Sloan-Kettering Cancer Center consisted of 41% of extremity 
sarcomas and 59% of other site soft tissue sarcomas and in this study, it is 57% and 43% 
respectively.  
Centre Extremity Other sites 
Memorial Sloan-Kettering Cancer Centre 41% 59% 
MD Anderson cancer centre 59% 41% 
Government Royapettah hospital 57% 43% 
 
      In extremity soft tissue sarcomas, 73% (89 cases) had localized disease, and 27% (33 
cases) had metastatic disease on presentation. Temple LK et al. reported 20% metastatic 
disease at presentation. 
Extremity-presentation Frequency Percentage  
         Metastatic 33 27 
Localized 89 73 
Total 122 100 
 
      
Metastatic disease Percentage 
Temple et al 20% 
Government Royapettah Hospital 27% 
  
    
        Out of 89 cases of localized extremity soft tissue sarcomas, 72 (81%) cases were 
identified as fit for limb sparing surgery. Remaining 17 (19%) cases were not suitable for 
limb sparing surgery and needed amputation.   
 
Localized soft tissue sarcoma-  
fitness for limb sparing surgery 
Frequency Percentage  
 Fit  72  81 
 NOT FIT, needed amputation 17 19 
Total 89 100 
 
          The most extensive resection is clearly amputation. This should be only rarely 
indicated in soft tissue sarcoma because limb-sparing operations are possible in at least 95% 
of patients. Experience over the last 25 years at MSKCC indicates that the amputation rate, 
which was 50% in the late 1960s, is now less than 5%. Amputation should be reserved for 
tumors that cannot be resected by any other means, without evidence of metastatic disease 
and the potential for good long-term functional rehabilitation. This usually includes patients 
with large, low-grade tumors with considerable cosmetic and functional deformity, who can 
be rendered symptom free by a major amputation. In this study, 19% of patients with 
localized soft tissue sarcoma required amputation. This high rate of amputation is due to large 
tumor size and late presentation of our patients. 
 
Centre Limb sparing surgery Amputations 
Memorial Sloan-Kettering Cancer Centre >95% <5% 
Watson DI et al 92.5% 7.5% 
Government Royapettah hospital 81% 19% 
 
 
      In this series of 72 patients, only 58(81%) patients were undergone limb sparing surgery 
and remaining 14(19%) patients refused further treatment. So, these 58 patients were taken 
for further study. 
 
 
 Course of patients fit for Limb sparing surgery Frequency  Percentage 
Limb sparing surgery  done 58 81 
Refused  surgery 14 19 
Total  72 100 
 
       In this series of 58 patients, male patients were 35(60%) and female were 23 (40%) with 
male to female ratio of 1.5: 1. and Ratio is 4:1 in the literature. 
  
 
 
         Patient’s age ranges from 16 to 75. Median age of patients is 45, average age is 46. Two 
third of the patients are in the age group of 31-60. 
 
AGE Frequency Percentage 
<30 years 12 21 
31-60 years 38 66 
>61 years 8 13 
Total 58 100 
        
       All patients are presented with swelling with varying duration. 52% (30 cases) of patients 
presented with pain and 3.5% (2) cases with other symptoms. 
 
Symptoms Frequency Percentage 
SEX Frequency Percentage
Male 35 60 
Female 23 40 
Total 58 100 
Swelling All 100% 
Pain 30 52% 
Other symptoms 2 3.5 
 
       In a study by Lawrence et al, 33% of patients complained of pain at the time of 
diagnosis. In this study, pain is the symptom that draws the patient to seek medical attention. 
Any soft tissue mass in an adult that is symptomatic or enlarging, any mass that is larger than 
5 cm, or any new mass that persists beyond 4 weeks is sampled 
 
       Approximately 10% soft tissue sarcoma patients have positive family history of cancer as 
observed in this study as well as in the literature. Approximately 5% of patients with NF 
develop malignant peripheral nerve sheath tumors (MPNSTs) ( Sorensen S et al). In this 
study one out of 12 patients with malignant peripheral nerve sheath tumors had 
neurofibromatosis. 
 
      39 (67%)cases were occurred in lower extremity and 19(33) cases in upper extremity with 
ratio of 2:1 comparable to Memorial Sloan-Kettering Cancer Center’s experience in which it 
is 71% and 29% respectively with ratio of 2.5:1. 
 
SITE Frequency Percentage 
Lower Extremity 39 67 
Upper Extremity 19 33 
TOTAL 58 100 
 
Centre Upper Extremity Lower  Extremity 
Memorial Sloan-Kettering Cancer Center 29% 71% 
Government Royapettah Hospital 33% 67% 
          
           SITE Frequency Percentage
Gluteal region 4 7% 
Thigh 30 52% 
Leg 4 7% 
Ankle 1 1.7% 
Foot - - 
Shoulder 6 10% 
Arm 6 10% 
Elbow 1 1.7% 
Forearm 5 8.9% 
Hands 1 1.7% 
TOTAL 58 100% 
        Commonest site of extremity soft tissue sarcoma in all series is thigh. In this study also 
commonest site is thigh (30 (52%) cases) followed by shoulder and arm (6 cases (10%) 
each) 
 
      24(41%) patients have primary tumors, 18(31%) are recurrent tumors and 16(28%) are 
residual tumors. Residual tumors are those presented after excision biopsy or marginal 
excision. 
Status of primary tumor Frequency Percentage 
Primary 24 41 
Recurrent 18 31 
Residue 16 28 
Total 58 100 
 
         
Stage  Frequency Percentage 
1A 5 9 
1B 29 50 
2A 2 3 
2B - - 
3 18 31 
4 1 2 
No stage 3 5 
Total 58 100 
        On admission 29(50%) cases are in stage 1B, followed by 18(31%) cases in stage 3. In 
three cases, stage was not assigned since they are dermatofibrosarcoma protuberance 
(2 cases) and angiosarcoma( one case).  
      
       Out of 55 cases, 46(84%) cases have T2b disease, 8 (14%) cases have T1b disease and 
T1a one case. 48 (83%) out of 58 cases had swelling more than 5 cm in size. So, any soft 
tissue mass that is >5cm in size should be investigated definitively (Brennan MF et al). 
T stage Frequency Percentage
T1a 1 2 
T1b 8 14 
T2a - - 
T2b 46 84 
Total 55 100 
 
      Liposarcoma is the commonest histology with 22% (13 cases). Liposarcoma, malignant 
peripheral nerve sheath tumor and malignant fibrous histiocytoma occur in almost equal 
frequency , comprising about 62% of cases.  
 
       Histopathology is dependent on the anatomic site. The common subtypes in the extremity 
are liposarcoma and malignant fibrous histiocytoma (Fletcher CD). In this study, 
Liposarcoma is the commonest histology followed by malignant peripheral nerve sheath 
tumor and malignant fibrous histiocytoma. 
 
Histology Frequency Percentage 
Liposarcoma 13 22 
Malignant peripheral nerve sheath tumor  12 21 
Malignant fibrous histiocytoma 11 19 
Synovial sarcoma 6 10.5 
Spindle cell sarcoma 6 10.5 
Others 10 17 
Total 58 100 
 
 
       Margin was free in 83% (48 cases), close in 7% (9 cases) and  not applicable in 10% (6 
cases) since there is no residual tumor. 
 Margin status Frequency Percentage 
Free  48 83 
Close  4 7 
Positive  0 0 
Not applicable 6 10 
Total  58 100 
 
     As might be expected, there can be considerable disagreement among pathologists 
regarding the specific histologic diagnosis in individual cases. 
 
      In this study in comparison with preoperative histology there is 64% of concordance with 
26% of discordance rate. 
 Frequency Percentage 
Histology concordance 37 64 
Histology discordance 15 26 
Not available 6 10 
Total  58 100 
 
       When pathologic material from 424 patients who entered into Eastern Cooperative 
Oncology Group (ECOG) sarcoma trials was reviewed by a panel of expert pathologists, 10% 
of cases were rejected as not being sarcoma, and for 14% of the remaining cases there was 
disagreement with respect to the histologic subtype.  
 
      In the Scandinavian Sarcoma Group experience, the specific histologic diagnosis was 
disputed in 20% of cases.37 With increasing familiarity with the immunohistochemical and 
genetic studies needed to diagnose soft tissue sarcoma, the rate of this discordance may be 
decreasing. 
Study Discordance Rate 
ECOG sarcoma trials 14% 
Scandinavian Sarcoma Group 20% 
Government Royapettah Hospital 26% 
 
        Wide mono bloc excision was done in 47 (81%) cases, compartmental excision in 
10(17%) cases and marginal excision in one case. 
Type of surgery  Frequency Percentage 
Wide mono bloc excision 47 81 
Compartmental excision 10 17 
Marginal excision 1 2 
Total 58 100 
 
     In 7 (12%) cases vascular resection was done. But only in 4 (7%) cases vascular 
reconstruction was done. 
Vessel Resected Frequency Percentage 
Femoral Artery & Vein 3 43% 
Deep femoral Artery & Femoral Vein 1 14% 
Deep femoral Artery 2 29% 
Ulnar artery 1 14% 
TOTAL 7 100% 
Type of vascular reconstruction Frequency Percentage 
Superficial femoral Artery & Vein 2 29% 
Superficial femoral artery only 1 14% 
Superficial femoral Vein only 1 14% 
No reconstruction 3 43% 
Total 7 100% 
   
       35 (60%) patients needed some form of reconstruction. 18 (31%) patients needed flap 
reconstruction, 5 skin graft, 4 vascular reconstruction, 4 tendon transfers, and flap and skin 
graft, flap and plate, flap and mesh, mesh one each. 
 
Types of Reconstruction Frequency Percentage 
Flaps 18 31% 
SSG 5 8.6% 
Vascular 4 6.8% 
Tendon transfer 4 6.8% 
Flap & SSG 1 1.7% 
Flap & Plate 1 1.7% 
Flap & Mesh 1 1.7% 
Mesh 1 1.7% 
Total 35 60% 
         
     Latissmus dorsi flap  and local transposition flap are common flaps used( in 6 cases each ). 
Gastrocnemius flap is used in 3 cases and reverse sural artery flap in 2 cases. Other flaps are 
used in 4 cases. 
 
 
 
 
 
Types of flaps used Frequency Percentage 
Latissmus dorsi 6 10.3% 
Transposition flap 6 10.3% 
Gastrocnemius 3 5.2% 
Reverse sural artery 2 3.4% 
Pectoralis Major Myo Cutaneous 1 1.7% 
Posterior thigh 1 1.7% 
Abdominal 1 1.7% 
Tensor fascia lata 1 1.7% 
Total 21 36% 
     
        So in situations of primary or recurrent tumors in which skin is involved or in which the 
tumor is so extensive that skin is involved, then consideration of free flap or rotational flap 
closure becomes important, particularly in those patients who are candidates for subsequent 
adjuvant radiation therapy.  
 
        Overall complications rate is 42%. Most common complication is marginal flap necrosis 
followed by lower limb edema. Other complications are Infection and wound gaping (2 
cases), infection (one case), wound gaping (one case) and femoral artery blow out (one case).   
  
 
Complications  Frequency Percentage 
Marginal flap necrosis 12 21 
Edema leg 5 9 
Seroma  2 3.4 
Infection and wound gaping 2 3.4 
Infection 1 1.7 
Wound gaping 1 1.7 
Femoral artery blow out 1 1.7 
Total complications 24 42 
No complications 34 58 
Total  58 100 
 
        79% (19 cases) were needed some form of secondary intervention to manage the 
complications. 
 
Management of complications Frequency  Percentage 
Wound debridement 6 25% 
Secondary suturing 6 25% 
Skin graft 5 21% 
Flap reconstruction 2 8% 
Conservative  5 21% 
Total  24 100% 
        In this study, 33% of patients developed postoperative complications requiring some 
form of intervention compared to 16% of complications reported by Yang JC et al in a 
randomized prospective study. But no patients required amputations in this study as reported 
by Yang JC et al (2% amputation rate). 
 
Post operative complications Yang JC et al Government Royapettah Hospital 
Requiring intervention 16% 33% 
Requiring amputation 2% Nil 
 
        Totally 7(12%) cases were presented with history of previous radiotherapy or 
chemotherapy or both. Totally 5(8.5%) cases had radiotherapy, so adjuvant radiotherapy is 
not possible in these cases.  
 
 
 Frequency  Percentage  
Previous H/O radiation 2 3.5% 
Previous H/O radiation and chemotherapy 3 5% 
Chemotherapy  2 3.5% 
Total 7 12% 
 
  
     32 cases have received adjuvant therapy. Out of these, one had preoperative radiotherapy, 
23 cases had postoperative adjuvant radiotherapy, 7 cases had both chemotherapy and 
radiotherapy, and one had chemotherapy. 
 
Additional treatment Frequency  Percentage  
Preoperative radiotherapy 1 1.7% 
Postoperative radiotherapy 23 39.6% 
Postoperative radiotherapy and chemotherapy 7 12.1% 
Postoperative chemotherapy  1 1.7% 
Total  32 55.1% 
 
 
        The goals of adjuvant radiotherapy in the management of soft tissue sarcoma are to 
enhance local control, preserve function, and achieve acceptable cosmesis by contributing to 
tissue preservation. The evidence for adjunctive radiation therapy in patients eligible for 
conservative surgical resection comes from two randomized trials and a number of large 
single-institution reports.  
 
        In one of these randomized trials, conducted by the National Cancer Institute, 91 
patients with high-grade extremity tumors were treated with limb-sparing surgery followed 
by chemotherapy alone or radiation therapy plus adjuvant chemotherapy. A second group of 
50 patients with low-grade tumors were treated with resection alone versus resection with 
radiation therapy. The 10-year local control rate for all patients receiving radiation therapy 
was 98% compared with 70% for those not receiving radiation therapy. 
 
          In the second randomized trial, which was performed at Memorial Sloan-Kettering 
Cancer Center, 164 patients were randomized to observation or brachytherapy following 
conservative surgery. The 5-year local control rate for patients with high-grade tumors was 
66% in the observation group and 89% in the group treated with brachytherapy. There was no 
significant difference between the groups of patients with low-grade tumors. 
  
      6 patients had disease recurrence.  4 patients had local recurrence. All but one local 
recurrence were successfully salvaged with limb sparing surgery. One patient had both local 
and distant recurrence at two years and died after 6 months (survival 30 months). Another 
patient recurred distantly at 30 months, now alive with disease (survival 37 months) 
      
Recurrence pattern Frequency Percentage 
Local 4 7% 
Local and distant 1 1.7% 
Distant 1 1.7% 
Total 6 10.4% 
 
      Follow up ranges from 1 month to 51 months. One patient had more than 4 years follow 
up, 8 patients had more than 3 years follow up, 22 patients had more than 2 years follow up, 8 
patients had more than 1 year follow up and 19 had less than one year follow up. 
 
 Duration follow up No.of patients Percentage 
More than 4 years 1 1.8% 
More than 3 years 8 13.8% 
More than 2 years 22 37.8% 
More than 1 year 8 13.8% 
Less  than 1 year 19 32.8% 
Total 58 100% 
 
       84.5% (49 cases) are disease free at closure of this study. 3.4% (2 cases) are alive with 
disease. 1.7% (0ne case) was died. 10.4% (6 cases) are lost follow up. 
 
 
Present status No. of patients Percentage  
Disease free 49 84.5% 
Alive with disease 2 3.4% 
Dead  1 1.7% 
Lost follow up 6 10.4% 
 Total  58 100% 
   
 
    70.8%(41 cases) and 22.4% (13 cases)of  patients had good and fair functional outcome. 
Remaining 6.8% (4 cases, 2 cases each) had excellent and poor functional result.  
 
Outcome  Frequency  Percentage  
Excellent 2 3.4% 
Good  41 70.8% 
Fair  13 22.4% 
Poor  2 3.4% 
Total  58 100% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. Conclusions 
 
 
     Soft tissue sarcomas are the most frequent sarcomas.  They are a rare and heterogeneous 
group of tumors representing 1.64% of all adult malignancies in this series. 
       
      They are a disease of adulthood, occurring most commonly in persons between 30 and 60 
years of age. Incidence in male is lower (male: female ratio – 1.5:1) in this series than   
reported in other series (ratio 4:1)  
      
      In this study, 81% of patients are suitable for limb sparing surgery and 19% of patients 
required amputation. This somewhat higher rate of amputation compared to international 
series is due to large tumor size and late presentation of our patients.  
      
      In this study, pain is the symptom that draws the patient to seek medical attention and 
most of the swellings are more than 5 cm in size. So, any soft tissue mass in an adult that is 
symptomatic or enlarging, any mass that is larger than 5 cm or any new mass that persists 
beyond 4 weeks is should be considered as soft tissue sarcoma and investigated definitively. 
 
     Evaluation for metastatic disease in the lungs should be done once a soft tissue sarcoma is 
diagnosed since one third of patients are metastatic at presentation in this study comparable to 
other studies. 
 
   84% of patients had T2b tumor that is deep tumor with size of more than 5 cm. 
Liposarcoma is the commonest histology comparable to other studies. In comparison with 
preoperative histology, there is 26% of discordance rate comparable to international series. 
With increasing familiarity with the immunohistochemical and genetic studies needed to 
diagnose soft tissue sarcoma, the rate of this discordance may decrease. 
 
      Wide local excision is the most common surgery (81%) done. In soft tissue sarcomas of 
extremity involving major vessels, vascular resection and reconstruction can be done 
successfully to salvage the limb. 
 
       In situations of primary or recurrent tumors in which skin is involved or in which the 
tumor is so extensive that skin is involved, then consideration of free flap or rotational flap 
closure becomes important, particularly in those patients who are candidates for subsequent 
adjuvant radiation therapy. 
  
    We depend on pedicled flap or local transposition flap for reconstruction. With use of free 
flaps in future, limb salvage rate can be increased with reduction in the rate of complications.   
 
      Even though limb sparing surgery has considerable percentage of complications than 
other studies, it is done without complication of amputation. 
 
       More than 70% of patients achieved good functional outcome following limb sparing 
surgery in this study. Limb sparing surgery can result in survival rates and disease-free 
periods that equal those achieved with amputation. The presumed functional and 
psychological advantages of Limb sparing surgery over amputation, however, have yet to be 
established. Limb sparing surgery appears to offer the possibility of better psychological 
functioning and an intact body image.  
 
      Limb-sparing surgery is now the standard of care for bone and soft tissue sarcomas of the 
extremities and is performed in approximately 90% of all cases.   All patients must be 
considered and evaluated for limb-sparing surgery, and the decision to proceed with an 
amputation should be made on a case-by-case basis. Such decisions are based on local 
anatomic considerations, tumor grade and stage, and consideration of the functional and 
psychological impact of the procedure. 
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PROFORMA 
 
STUDY ON LIMB SPARING SURGERY IN EXTREMITY SOFT TISSUE 
SARCOMAS 
 
NAME       :                                           OCCUPATION :                              DOA: 
AGE/SEX  :                                           IP/CD NO.         :                              DOS: 
ADDRESS :                                           PHONE NO.      :                              DOD: 
 
 
 
DIAGNOSIS  
TNM STAGING  
STAGE GROUPING  
   
COMPLAINTS 
 
SWELLING                                                   : YES/NO 
      DURATION                                             : 
PAIN                                                               : YES/NO 
      DURATION                                             : 
INSTABILITY OF ARM                             : YES/NO 
DECREASED MOBILITY OF ARM         : YES/NO 
PREVIOUS BIOPSY                                    : YES/NO 
TYPE OF BIOPSY                                       : FNAC 
                                                                        : CORE NEEDLE BIOPSY 
                                                                        : INCISIONAL BIOPSY 
                                                                        : EXCISIONAL BIOPSY 
BIOPSY PERFORMED BY                        : SURGICAL ONCOLOGIST 
                                                                        : GENERAL SURGEON 
                                                                        : ORTHOPAEDIC SURGEON 
                                                                        : OTHERS 
FAMILY H/O CANCER                              : YES/NO 
WHO AFFECTED                                        : 1ST /2ND /3RD DEGREE RELATIVE 
BY WHICH MALIGNANCY                      : 
MULTIPLE RELATIVES AFFECTED     : 
PREVIOUS H/O MALIGNANCY             : YES/NO 
TYPE OF MALIGNANCY                          : CARCINOMA / SARCOMA 
HISTOLOGY                                                : 
H/O PREVIOUS TREATMENT                 : SURGERY 
                                                                        : CHEMOTHERAPY 
                                                                        : RADIOTHERAPY 
                                                                        : OTHERS 
H/O IRRADIATION                                    : YES/ NO           DATE: 
 
PHYSICAL EXAMINATION 
 
PERFORMANCE STATUS                        : 
PREVIOUS BIOPSY SCAR LENGTH     :         CM 
                                                                        : TRANSVERSE / LONGITUDINAL /OBLIQUE 
HEALING STATUS                                    : HEALED / HEALING / INFECTED 
HEALED BY WHAT INTENTION           : PRIMARY / SECONDARY 
 
 
EXAMINATION OF SWELLING 
SITE 
UPPER LIMB                                       : RIGHT / LEFT 
                                                                : ARM / ELBOW / FOREARM / HAND 
                                                                : SHOULDER GIRDLE 
COMPARTMENT INVOLVED         : 
LOWER LIMB                                     : RIGHT / LEFT 
                                                                : THIGH/POPLITEAL FOSSA/LEG/FOOT 
                                                                : GLUTEAL REGION  
COMPARTMENT INVOLVED         : 
PLANE                                                   : SUPERFICIAL / DEEP 
                                                                : INVOLVIG FASCIA / BONE 
SIZE                                                       :           CM, <5 / 5-10 / >10 CM 
SKIN INVOLVEMENT                       : YES / NO 
VASCULAR INVOLVEMENT             : YES / NO 
VESSEL AFFECTED                          : 
NERVE INVOLVEMENT                  : YES / NO 
NERVE AFFECTED                           : 
EXTENT                                               : 
 
REGIONAL  LYMPH NODES          : YES / NO 
DISTANT METASTASES                  : YES / NO 
SITE OF DISTANT METASTASES : 
JOINT MOVEMENT AFFECTED    : YES / NO 
WHICH JOINT INVOLVED              : 
 
INVESTIGATIONS 
 
BIOPSY                                                  : FNAC / CORE NEEDLE BIOPSY 
                                                                 : INCISION BIOPSY / EXCIONAL BIOPSY 
HISTOLOGY                                         : 
GRADE                                                   : 
IMMUNO HISTOCHEMISTRY         : 
 
XRAY CHEST                                       : NORMAL / METASTASES 
METASTASES IN WHICH LUNG     : RIGHT / LEFT / BILATERAL 
NUMBER OF METASTASES             : 
 
CT SCAN CHEST                                  : NORMAL / METASTASES 
METASTASES IN WHICH LUNG     : RIGHT / LEFT / BILATERAL 
NUMBER OF METASTASES             : 
 
CT SCAN  LOCAL PART               : SUPERFICIAL / DEEP 
                                                             : INVOLVING FASCIA / BONE 
NERVE                                               : NOT AFFECTED / DISPLACED / INVOLVED 
NERVE AFFECTED                         : 
VESSELS                                            : NOT AFFECTED / DISPLACED / INVOLVED 
VESSEL AFFECTED                        : 
NECROSIS                                         : YES / NO 
HEMORRHAGE                               : YES / NO 
CONTRAST ENHANCEMENT      : YES / NO 
 
MRI LOCAL PART                           : 
     
                                                                                                                              
 
TREATMENT 
 
 RESECTION 
 
    EXTENT OF RESECTION             : WIDE MONOBLOC RESECTION 
                                                                 : COMPARTMENTAL RESECTION 
                                                                 :  MARGINAL EXCISION 
    VASCULAR RESECTION              : YES / NO 
    VESSEL RESECTED                       : ARTERY / VEIN / BOTH 
    PARTS RESECTED                         :  
 
 
 
 
RECONSTRUCTION  
 
SKIN                                                      : PRIMARY CLOSURE / FLAP 
SOFT TISSUE                                      : PRIMARY CLOSURE / FLAP 
NAME OF FLAP USED                      : 
VASCULAR RECONSTRUCTION   : YES / NO 
VESSEL USED                                      : 
 
POSTOPERATIVE COMPLICATIONS        
 
WOUND INFECTION                          : YES / NO 
FLAP NECROSIS                                  : NO / MARGINAL / TOTAL 
WOUND GAPING                                 : YES / NO 
SECOND SURGERY                             : YES / NO 
TYPE OF SECOND SURGERY          : WOUND DEBRIDEMENT / SSG 
                                                                  : SECONDARY SUTURING / FLAP COVER 
                                                                  : AMPUTATION 
 
HOSPITAL STAY  
 
NO OF DAYS     : PREOPERATIVE    :           DAYS 
                             : POSTOPERATIVE  :            DAYS  
 
POST-OPERATIVE HISTOPATHOLOGICAL EXAMINATION 
 
NUMBER                                               : 
HISTOLOGY                                         : 
GRADE                                                   : LOW / HIGH 
MARGIN                                                 : NEGATIVE / POSITIVE / CLOSE 
                                                                  :         CM 
 
ADJUVANT THERAPY                       : CHEMOTHERAPY / RT / BOTH 
 
CHEMOTHERAPY  - DRUGS              : 
                                    NO OF CYCLES  : 
 
RADIOTHERAPY 
 
MODE                                                      : EBRT / BRACHYTHERAPY / BOTH 
TOTAL DOSE                                         : 
NUMBER OF FRACTIONS                                : 
DOSE PER FRACTION                                       : 
TREATMENT BREAK                                        : YES / NO 
CUASE OF TREATMENT BREAK                   : 
COMPLICATIONS                                               : 
 
REHABILITATION 
 
REST IN SPLINT                                                    : YES / NO 
DURATION IN SPLINT                                         : DAYS 
TIME OF RESTORATION OF MOVEMENT    : 
TIME OF RESTORATION OF MOBILITY        : 
 
FUNCTION OF LIMB 
 
USING THE LIMB                                                   : YES / NO 
PAIN                                                                           : YES / NO 
MOVEMENT OF LIMB                                          : ABSENT / PRESENT 
                                                                                     : ACTIVE / PASSIVE 
                                                                                     : PAINFUL / PAINLESS 
RANGE OF MOVEMENTS                                     : 
 
 
FOLLOW UP 
 
PARAMETERS 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
DATE 
 
                    
DISEASE FREE 
YES/NO 
                    
RECURRENCE 
YES/ NO 
                    
TIME OF 
RECURRENCE 
                    
SITE OF 
RECURRENCE 
                    
LOCAL                     
REGIONAL                     
DISTANT                     
SITE OF 
DISTANT 
RECURRENCE 
                    
 
SALVAGE OF RECURRENCE                 : YES / NO 
MODE OF SALVAGE                                 : 
 
                                                                    
                                            
 
 
 
 
 
Age/ 
Sex 
C.D. 
No 
Site Swelling 
duration 
Pain / 
duration 
Other 
symptoms 
Family 
history 
Previous 
biopsy 
Y/N 
type 
Biopsy/ 
surgery 
done by 
Prior 
surgery 
Yes/No 
Duration 
Prior 
RT 
Chemo 
Scar status Size/ 
Deep/ 
superficial 
Primary/ 
Recurrent/ 
residual 
biopsy 
an 62/M 135/04 Thigh 
RT 
3 months Yes, 1 
month 
- - - General 
Surgeon  
Yes,       
1 year 
- 15 cm. 
longitudinal 
10cm 
deep 
Recurrent  - 
53/M 734/04 Arm LT 2 months 1 month  Fungation, 
bleeding 
- - General 
Surgeon 
Yes  
4 years 
- - 12cm,  
Deep 
fungation 
Recurrent - 
16/F 778/04 Thigh 
RT  
5 months - - - Yes 
excision 
General 
Surgeon 
Yes, 1 
month 
- 20 cm. 
longitudinal 
15cm,  
Deep 
Residue - 
50/M 721/04 Arm RT 3 months - - - - General 
Surgeon 
Yes, 9 
months 
- 15 cm. 
longitudinal 
8cm, 
Deep 
Recurrent  -  
a 55/F 939/04 
 
Thigh  
LT 
6  
months 
- - - - General 
Surgeon 
Yes 
20 days 
- 12 cm. 
longitudinal 
8cm, 
Deep 
Residue - 
58/M 1382/04 
 
Thigh 
RT 
4  
months  
Yes, 
4 months 
- - Yes 
excision 
General 
Surgeon 
Yes 
20 days 
- 6 cm 
longitudinal 
12cm,  
Deep 
Residue - 
64/M 446/05 Thigh 
RT 
5 months yes , 4 
months 
 
- 
- - - - - - 7cm, 
deep 
Primary  Trucut  
o  60/M 1445/05 Thigh 
LT 
One year - Fungation  NF+ Yes, 
incision  
General 
Surgeon 
-- - 5 cm. 
Longitudinal 
25cm,  
Deep 
Primary  - 
19/F 569/05 Thigh 
LT 
6 months  - Fungation  - - General 
Surgeon 
4 years  RT - 6cm 
Deep 
Recurrent - 
47/F 1114/05 Thigh 
LT 
2 months 2 months - - - - - - - 15cm 
Deep 
Primary  Trucut 
m 60/M 719/05 Thigh 
LT 
4 months 2 months - - - General 
Surgeon 
Yes, 
1.5 years 
- 6 cm 
Longitudinal 
 
8cm 
Deep  
Recurrent  - 
Age/ 
Sex 
C.D. 
No 
Site Swelling 
duration 
Pain / 
duration 
Other 
symptoms 
Family 
history 
Previous 
biopsy 
Y/N 
type 
Biopsy/ 
surgery 
done by 
Prior 
surgery 
Yes/No 
Duration 
Prior 
RT 
Chemo 
Scar status Size/ 
Deep/ 
superficial 
Primary/ 
Recurrent/ 
residual 
biopsy 
19/F 724/05 Forearm 
RT 
1 month 1 month - Yes, 
father 
- General 
Surgeon 
Yes , 3 
times 
- 6 cm 
Longitudinal 
 
5cm, 
Deep  
Recurrent  - 
45/M 788/05 Thigh 
LT 
2 months - - - - General 
Surgeon 
Yes, 
6 months 
- 5 cm 
Longitudinal 
 
15 cm, 
Deep  
Recurrent  - 
n 40/F 917/05 Thigh 
LT 
3 months 1 month - - Yes, 
excision  
General 
Surgeon 
Yes, 
2 months 
- 6cm 
Oblique  
4 cm deep Residue  - 
al 51/F 959/05 Gluteal 
region 
LT 
1 month - - - - General 
Surgeon 
Yes , 3 
times 
- 15 cm 
Oblique 
10  cm 
deep 
Recurrent - 
n 45/M 1023/05 Thigh 
RT 
2  
months 
1 month - - Yes, 
excision  
General 
Surgeon 
Yes, 
1 month 
- 8 cm 
Longitudinal 
8  cm  
deep 
Residual - 
37/M 1234/05 Elbow 
left 
6  
months 
3 
 months 
Difficulty 
In using 
- - - - - -  15 
Deep 
Primary Trucut  
MASTER CHART 
elbow 
19/F 1395/05 Thigh 
LT 
One year 4 months - - Yes, 
incision 
General 
Surgeon 
Yes, 
1 month 
- 6 cm 
Longitudinal 
15  cm  
deep 
Primary - 
20/F 22/06 Thigh 
LT 
5 month - - - Yes, 
excision  
General 
Surgeon 
Yes, 
2 months 
Chemo 
Therapy 
7 cm 
Longitudinal 
6  cm  
deep 
Residual -  
35/F 130/06 Arm LT 
 
 
4 months - - - Yes, 
excision  
General 
Surgeon 
Yes, 
One year 
- 5 cm 
Oblique 
8  cm 
 deep 
Recurrent 
 
- 
Age/ 
Sex 
C.D. 
No 
Site Swelling 
duration 
Pain / 
duration 
Other 
symptoms 
Family 
history 
Previous 
biopsy 
Y/N 
type 
Biopsy/ 
surgery 
done by 
Prior 
surgery 
Yes/No 
Duration 
Prior 
RT 
Chemo 
Scar status Size/ 
Deep/ 
superficial 
Primary/ 
Recurrent/ 
residual 
biopsy 
y 63/F 483/06 Thigh 
RT 
2 month - - - - - - - - 8cn 
Deep  
Primary  Trucut  
an 63/M 97/06 Thigh 
RT 
0ne 
Year 
6 months - - - - - Chemo 
Therapy 
- 14cm 
Deep  
Primary Trucut 
45/M 426/99 Thigh 
LT 
3 months - - - - - - - - 12cm 
Deep 
3rd primary Trucut  
42/M 354/06 Leg LT 5 years - - - Yes 
Excision 
General 
surgeon 
Yes, 
1 month 
- 6cm 
Oblique 
5Cm 
Deep 
Residue - 
45/F 543/06 Gluteal  
 
RT 
1.5 years 4 months Bleeding - Incision General 
surgeon 
- - - 12cm 
superficial 
Primary - 
32/M 777/06 Thigh 
LT 
3 months 1 month - - - Plastic 
surgeon 
Yes 
3 times 
- Skin 
involved 
10cm 
Deep 
Recurrent  Trucut  
35/M 1291/06 Leg LT 3 months 2 months  
- 
- Yes 
Excision 
General 
surgeon 
Yes, 
8 months 
- Skin 
involved 
8cm 
Deep 
Recurrent -  
ar 35/M 1328/06 Thigh 
LT 
1 year - - - - - - - - 15cm 
deep 
Primary Trucut  
n 34/M 1453/06 Thigh 
LT 
1 month - - - - - - - - 7 cm 
deep 
Primary Trucut  
n 23/M 1533/06 Forearm 
RT 
2 months 2 months - - Yes 
Excision 
General 
surgeon 
Yes, 
4 months 
- 6 cm 
longitudinal 
4cm 
deep 
Residue - 
39/M 336/02 Leg       
LT 
2 years 2months - - - Surgical 
Oncologist 
3 times, 
1997 
RT Skin 
involved 
8cm 
Deep 
Recurrent  - 
55/F 16/07 Thigh 
LT 
20 days - - - - - - - - 13cm 
Deep 
Primary Tr ucut 
Age/ 
Sex 
C.D. 
No 
Site Swelling 
duration 
Pain / 
duration 
Other 
symptoms 
Family 
history 
Previous 
biopsy 
Y/N 
type 
Biopsy/ 
surgery 
done by 
Prior 
surgery 
Yes/No 
Duration 
Prior 
RT 
Chemo 
Scar status Size/ 
Deep/ 
superficial 
Primary/ 
Recurrent/ 
residual 
biopsy 
29/M 278/07 Thigh  
RT 
2 months - - Yes, 
mother 
- Surgical 
Oncologist 
Yes, 8 
months 
Chemo 
RT 
15cm -longi 
tudinal,6cm- 
transverse 
4cm 
Deep 
Recurrent - 
40/F 609/07 Hand 20 years 1 month - - - - - - - 2cm Primary  - 
LT superficial 
53/M 432/07 Leg RT 4 months - - - Yes 
Excision 
General 
surgeon 
Yes, 
2 months 
- 10 cm 
Transverse 
7cm 
deep 
Residue - 
57/M 202/07 Thigh 
RT 
2 months - - - FNAC General 
surgeon 
- - - 18cm 
Deep 
Primary  - 
24/M 413/07 Shoulder 
LT 
2 months - Fungation  - - General 
surgeon 
Yes, 
3 times 
Chemo 
RT 
Fungation  12cm, 
Deep 
Recurrent  - 
y 52/F 620/07 
?626/07 
Thigh 
LT 
1.5 year - - - - - - - - 15cm 
Deep 
Primary  Trucut  
n 36/0M 775/07 Foot  
RT 
3 months 
 
2months - - - General 
surgeon 
1 year Chemo 
RT 
Fungation  6cm 
Deep 
Recurrent  - 
76/M 867/07 Thigh 
LT 
3 months 1 month - Yes  - - - - - 20cm 
Deep 
Primary  Trucut  
63/M 996/07 Arm RT 6 months 1 month - Yes  - - - - - 12cm 
Deep 
Primary Trucut  
30/M 982/07 Gluteal 
region 
LT 
2 months 1 month - - - General 
surgeon 
Yes, 2 
times, 
3years 
- Skin graft in 
situ 
Local & 
nodal 
recurrence 
Recurrent - 
75/F 998/07 Gluteal 
RT 
1.5 years - - - - General 
surgeon 
Yes, 11 
years 
- 15cm 
oblique 
15cm 
Deep 
Recurrent Trucut  
Age/ 
Sex 
C.D. 
No 
Site Swelling 
duration 
Pain / 
duration 
Other 
symptoms 
Family 
history 
Previous 
biopsy 
Y/N 
Type 
Biopsy/ 
surgery 
done by 
Prior 
surgery 
Yes/No 
Duration 
Prior 
RT 
Chemo 
Scar status Size/ 
Deep/ 
superficial 
Primary/ 
Recurrent/ 
residual 
biopsy 
y 55/F 1067/07 Forearm 
RT 
1 year - - - - General 
surgeon 
Yes, 5 
years 
- 15cm -longi 
tudinal 
6cm, 
  deep 
Recurrent Trucut  
20/M 1212/07 Thigh 
RT 
4 years 1 year - - - - - - -  14cm 
Deep 
Primary Trucut  
y 59/F 1260/07 Arm RT 
 
2 month - - - Yes 
Excision 
General 
surgeon 
Yes, 4 
months 
- 6cm 
oblique 
 4cm 
Deep 
Residue - 
y 47/M 1335/07 Arm LT 6 months 4 months - - - - - - - 12cm 
Deep 
Primary Trucut  
39/M 1483/07 Thigh 
LT 
1 year 6 months - Yes Yes, 
Incision 
General 
surgeon 
Yes, 1 
month 
- 6cm 
oblique 
6cm 
deep 
Residue - 
23/F 1527/07 Thigh 
LT 
6 months 2 months - - - - - - - - Primary Trucut  
n 26/M 1562/07 Shoulder 
RT 
4 months - - - Yes 
Excision 
General 
surgeon 
Yes, 2 
months 
- 4CM 
Transverse  
4cm 
superficial 
Residue  - 
38/M 1855/07 Shoulder 
LT 
3 months - - - Yes 
Excision 
General 
surgeon 
Yes, 2 
months 
- 5cm 
Oblique 
4cm 
Deep 
Residue - 
my 55/M 1805/07 Shoulder 
RT 
 
6 months 3 months - - Yes, 
Incision 
General 
surgeon 
Yes, 3 
months 
- 15cm -longi 
tudinal 
10cm 
Deep 
Primary Trucut  
53/F 74/08 Thigh 
RT 
 
2 years  6 months - - Yes, 
Incision 
General 
surgeon 
Yes, 10 
days 
- 6 cm -longi 
tudinal 
infected  
20cm 
Deep 
Primary  - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50/F 1715/07 Forearm 
RT 
 
2 years 1 month - - - Plastic 
surgeon 
Yes, 4 
times 
- Skin 
involved 
10cm 
Deep 
Recurrent  - 
Age/ 
Sex 
C.D. 
No 
Site Swelling 
duration 
Pain / 
duration 
Other 
symptoms 
Family 
history 
Previous 
biopsy 
Y/N 
Type 
Biopsy/ 
surgery 
done by 
Prior 
surgery 
Yes/No 
Duration 
Prior 
RT 
Chemo 
Scar status Size/ 
Deep/ 
superficial 
Primary/ 
Recurrent/ 
residual 
biopsy 
35/F 257/08 Shoulder 
 LT 
 
1 year 6 months - - Yes 
Excision 
General 
surgeon 
Yes, 2 
months 
- 6cm 
Oblique 
6cm 
deep 
Residue - 
67/F 268/08 Forearm 
RT 
 
5 months 1 month -- - FNAC General 
surgeon 
- - - 8cm deep Primary Trucut  
ur 60/M 534/08 Shoulder 
RT 
 
1 year 2 months - - Yes 
incision 
General 
surgeon 
Yes, 1 
month 
- Skin 
involved 
12cm 
deep 
Primary - 
53/M 542/08 Thigh  
 
LT 
2 month 1 month - - Yes 
Excision 
General 
surgeon 
Yes, 5 
months 
- 12cm -longi 
tudinal 
6cm 
deep 
Residue - 
S. 
No 
Name Surgery Vascular 
/Bone/ 
nerve 
resection 
Recons
truction 
 Skin/soft 
tissue 
Vascular/ 
Bone 
Recons 
truction 
Compli 
cations
Second 
surgery 
Post op  
HPE  
Grade 
Mar
gi  
HPE 
Concor 
dance/ 
discordance 
Adju 
vant  
Post 
operative 
function 
Recu 
rrence/ 
site 
RT-right, LT-left, FNAC- fine 
needle aspiration cytology, CD 
NO-cancer department number 
1 Pavadai rajan Compartmental 
resection 
- - - Edema 
leg 
 MFH,  
Low grade 
 Concordance Chemo, 
RT 
Good  - 
2 Gangan  Wide Local 
Excision 
- Latissmus 
dorsi flap 
- -  MFH,  
High grade 
-VE Concordance RT Good - 
3 Chittu Wide Local 
Excision 
- - 
  
- -  Residual 
sarcoma 
-ve Discordance RT Good - 
4 Musthafa  Wide Local 
Excision 
Musculo 
cutaneous 
Nerve 
Local 
transposi
tion flap 
- -  Spindle cell 
Sarcoma 
Low grade 
-ve discordance - Good - 
5 Regellamma Compartmental 
resection 
- -- 
- 
- -  Liposarcoma 
Low grade 
-ve Concordance - Good - 
6 Mani Compartmental 
resection 
- - 
 
- -  MFH,  
High grade 
-ve discordance Chemo, 
RT 
Fair - 
7 kabidoss Wide Local 
Excision 
- - 
 
- -  MFH,  
High grade 
-ve Concordance RT Good Distant 
Nodal 
8 Samivasa rao  Wide Local 
Excision 
- Tendon 
transfer 
- Marginal  
flap 
  necrosis 
Gastroc 
Nemius 
flap 
MPNST 
Low grade 
-ve Concordance RT Fair - 
9 Lalitha Wide Local 
Excision 
- Local 
transposi
tion flap 
- Marginal 
flap 
necrosis 
Skin  
graft 
Synovial  
Sarcoma low 
Grade 
-ve Concordance - Good - 
10 Kanish 
zainath 
Wide Local 
Excision 
- - - Marginal  
flap 
necrosis 
Wound 
debride 
Ment 
Liposarcoma 
high grade 
Clos
e 
Concordance RT Good Lung 
 
bilateral
11 Danihachalam Wide Local 
Excision 
- - 
 
- -  MFH,  
High grade 
-ve Concordance RT Good - 
S. 
No 
Name Surgery Vascular 
/Bone/ 
nerve 
resection 
Recons 
truction 
 Skin/soft 
tissue 
Vascular/ 
Bone 
Recons 
truction 
Compli 
cations
Second 
surgery 
Post op  
HPE  
Grade 
Mar
gin 
HPE 
Concor 
dance/ 
discordance 
Adju 
vant  
Post 
operative 
function 
Recu 
rrence/ 
site 
12 Kokila Compartmental 
resection 
Ulnar 
artery 
- 
 
- - - MPNST 
Low grade 
-ve Concordance RT Fair - 
13 Murugesan Wide Local 
Excision 
- Tensor 
fascia 
lata 
- - - RMS 
High grade 
-ve Concordance Chemo, 
RT 
Good  - 
14 Bee bee john Wide Local 
Excision 
- - 
 
- - - No residual 
Tumor 
- - - Good - 
15 Govindammal Wide Local 
Excision 
- Local 
transposi
tion flap 
- Marginal  
flap  
necrosis 
Skin  
Graft 
Spindle cell 
Sarcoma 
Low grade 
Clo 
Se 
Concordance - Good - 
16 Anjalaiyan Adductor  
Compart 
mental  
excision 
- - - - - No residual 
Tumor 
- - - Good - 
17 Puru 
sothaman 
Wide Local 
Excision 
- Latissmu
s dorsi 
flap 
- - - Synovial  
Sarcoma 
Clo 
Se 
Concordance Chemo, 
RT 
Fair  - 
18 Ranjana Wide Local 
Excision 
 YES, 
Artery & 
 Artery-long 
saphenous 
Wound
 gaping
Secon 
dary 
Synovial  
Sarcoma 
-ve Concordance Chemo, 
RT 
Good - 
vein vein suturing High grade 
19 Kavitha Wide Local 
Excision 
- - - - - No residual  
Tumor 
- - Chemo, Good  - 
20 Jaya Wide Local 
Excision & 
axillary node 
dissection 
 
 
- Trans 
Position  
flap 
- - - MPNST 
Low grade 
-ve Concordance RT Fair  Local  
S. 
No 
Name Surgery Vascular 
/Bone/ 
nerve 
resection 
Recons 
truction 
 Skin/soft 
tissue 
Vascular/ 
Bone 
Recons 
truction 
Compli 
Cations
Second 
surgery 
Post op  
HPE  
Grade 
Mar
gin 
HPE 
Concor 
dance/ 
discordance 
Adju 
vant  
Post 
operative 
function 
Recu 
rrence/ 
site 
21 Padmavathy 
 
Wide Local 
Excision 
- Trans 
Position  
flap 
- - - RMS 
High grade 
-ve Concordance RT Good  
 
- 
22 Chandrahasan Marginal  
Excision 
 DFA, 
SFV 
- Vein-long   
saphenous 
vein 
Wound
 Gaping
Femoral 
Artery 
blowout
Wound 
Debride 
ment 
Pleomorphic 
RMS 
High Grade 
-ve Concordance - Fair  - 
23 Elango Wide Local 
Excision 
DFA - - Marginal  
flap  
nnecrosis
Secon 
dary 
suturing 
Liposarcoma 
High grade 
-ve Concordance RT Good  - 
24 Ganesan Wide Local 
Excision 
- Reverse  
Sural 
Artery 
  
- Marginal  
flap  
nnecrosis
Wound 
Debride 
ment 
Hemangio 
pericytoma 
-ve Concordance - Good - 
25 Mangalam Wide Local 
Excision  
- Posterior  
Thigh 
- Marginal  
flap  
nnecrosis
Skin  
graft 
Angiosarcoma 
 
-ve Concordance RT Good - 
26 Ponmuthu Wide Local 
Excision  
- Gastroc 
nemius flap 
 
- - - DFSP 
 
-ve, 
 
 
Concordance - Good Local 
27 Laxmanan Wide Local 
Excision  
- Gastroc 
Nemius 
- - - Fibrosarcoma 
High Grade 
-ve discordance RT Good - 
28 Chandrasekar Compart 
mental  
excision 
- - - - -  liposarcoma 
low grade 
-ve Concordance - Good - 
S. 
No 
Name Surgery Vascular 
/Bone/ 
nerve 
resection 
Recons 
truction 
 Skin/soft 
tissue 
Vascular/ 
Bone 
Recons 
truction 
Compli 
cations
Second 
surgery 
Post op  
HPE  
Grade 
Mar
gin 
HPE 
Concor 
dance/ 
discordance 
Adju 
vant  
Post 
operative 
function 
Recu 
rrence/ 
site 
29 Sundarajan  Wide Local 
Excision 
-  
- 
- - - Liposarcoma 
Low grade 
-ve Concordance - Good  - 
30 Moovendan Wide Local 
Excision 
- - 
 
- - - MPNST 
Low garde 
-ve Concordance - Good - 
31 Nagaraj Wide Local 
Excision 
- SSG - - - MPNST 
Low grade 
-ve discordance - Good - 
32 Melambal Wide Local 
Excision 
- - - - - Liposarcoma 
Low grade 
-ve Concordance RT Good  - 
33 Abdulla  Wide Local 
Excision 
- Gastroc 
nemius, 
SSG 
- - - No residual  
Tumor 
 
- - - Good Local- 
10 
months 
34 Phuspha Wide Local 
Excision 
- - 
 
- - - DFSP -ve Concordance - Good - 
35 Sankara 
pandian 
Wide local 
excision 
- SSG - - - MFH 
Low Grade 
-ve Concordance - Good - 
36 Nagarajan     Compart 
mental  
excision 
- Tendon  
transfer 
- Marginal  
flap  
Necrosis
Edema leg
Secon 
dary 
suturing 
MFH 
High Grade 
-ve discordance RT Good - 
37 Guna  Wide local 
excision & 
node dissection 
Clavicle Latissmus  
Dorsi flap 
- - - MPNST  
Low grade 
-ve Concordance - Good - 
38 Banumathy Wide local 
excision 
-      - - - - Liposarcoma 
Low grade 
-ve Concordance - Good - 
39 Ramkannan  Wide local 
excision 
calcaneu
m 
Reverse 
sural 
artery 
- Marginal  
flap 
 necrosis 
Wound 
debride 
ment 
Synovial 
sarcoma 
Low grade 
clos
e 
Concordance - Good - 
S. 
No 
Name Surgery Vascular 
/Bone/ 
nerve 
resection 
Recons 
truction 
 Skin/soft 
tissue 
Vascular/ 
Bone 
Recons 
truction 
Compli 
cations
Second 
surgery 
Post op  
HPE  
Grade 
Mar
gin 
HPE 
Concor 
dance/ 
discordance 
Adju 
vant  
Post 
operative 
function 
Recu 
rrence/ 
site 
40 Elumalai Wide local 
excision  
- Mesh - Seroma - Liposarcoma
low Grade 
-ve Concordance RT Good  - 
41 Krishnan Wide local 
excision 
- PMMC 
Flap 
- - - MFH, 
Low Grade 
-ve discordance RT Fair  - 
42 Manickam Wide local 
excision& 
node dissection 
- Skin graft 
 
- Marginal 
flap  
necrosis
Wound 
debri 
ment 
Spindle cell 
sarcoma 
Low garde 
-ve Discordance Chemo Good - 
43 Parvathy Wide local 
excision 
- - - - - Liposarcoma 
Low Grade 
-ve Concordance RT Good - 
44 Thilagavathy Muscle group 
excision 
- Tendon 
 transfer 
- Marginal 
flap  
necrosis
Wound 
debri 
ment 
Liposarcoma 
Low Grade 
-ve Discordance - Fair  - 
45 Sundar Wide local 
excision 
- - - - - MPNST 
Low grade 
-ve Discordance   RT Fair  - 
46 Amaravathy  Wide local 
excision 
-  
 
- -  
- 
No residual  
tumor 
- - RT Fair  - 
47 Duraisamy Wide local 
excision 
Ulnar 
nerve 
- 
 
- Seroma - Neurofibro 
Sarcoma-LG 
-ve Discordance RT Good - 
48 Thangaraj Wide local 
excision 
SFA, 
SFV 
- Artery-
Long 
sapheno
us vein 
Infection
Woung 
Gaping
Edemaleg 
Secon 
dary 
suturing 
MPNST  
high grade 
-ve Concordance RT, 
Chemo 
Fair  - 
49 Usha Wide local 
excision 
SFA, 
SFV 
- Artery&
veinlong 
sapheno
Infection
Woung 
Gaping
Secon 
dary 
suturing 
MFH, 
Low Grade 
-ve Concordance RT Good - 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
us vein Edemaleg 
S. 
No 
Name Surgery Vascular 
/Bone/ 
nerve 
resection 
Recons 
truction 
 Skin/soft 
tissue 
Vascular/ 
Bone 
Recons 
truction 
Compli 
cations
Second 
surgery 
Post op  
HPE  
Grade 
Mar
gin 
HPE 
Concor 
dance/ 
discordance 
Adju 
vant  
Post 
operative 
function 
Recu 
rrence/ 
site 
50 Narayanan Wide local 
excision 
- - 
 
 
- - - No residual 
Tumor 
- - - Excellent  - 
51 Ilaiyaraja Wide local 
excision 
- Trans 
Position 
Flap 
- Marginal 
flap  
necrosis
Skin 
 graft 
Spindle cell 
Sarcoma 
Low grade 
-ve Concordance - Good  
 
- 
52 Govindasamy Wide local 
excision 
Bone Latissmus  
Dorsi flap  
 
Mesh - - Extraskeletal 
Chondro 
sarcoma 
-ve Concordance - Poor  - 
53 Prabha      Compart 
mental  
excision 
DFA Tendon 
 Transfer 
- Marginal 
flap  
necrosis
Skin 
Graft 
Liposarcoma 
Low grade 
-ve Concordance - Fair  - 
54 Thangam Wide local 
excision 
Ulna, 
radius 
Abdominal  
Flap 
Plate  
 
Marginal 
flap  
necrosis
Skin 
Graft 
MPNST 
Low grade 
-ve Concordance - Fair - 
55 Flori Wide local 
excision 
- Trans 
Position 
Flap 
- - - Extraskeletal 
Chondro 
sarcoma 
-ve Concordance - Good  - 
56 Ramani Wide local 
excision 
- Skin graft 
 
 
- - - MPNST 
High grade 
-ve discordance - Excellent - 
57 Abdull sukur Wide local 
excision 
- Mesh, 
Latissmus  
Dorsi flap 
- Marginal 
flap  
necrosis
flap MFH 
High grade 
-ve discordance - Poor  - 
58 Palanivel Wide local 
excision 
- - 
 
 
- - - Liposarcoma 
Low grade 
-ve discordance - good - 
Abbereviations: DFA- deep femoral artery, SFA-supeficial femoral artery, SFV-superficial femoral vein, MFH- ma
histiocytoma, MPNST-malignant peripheral nerve sheath tumor, -ve- negative, LG- low grade, RT-radiotherapy, ch
HPE-histopathologiical examination,
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CT Scan Left thigh showing typical fat density suggestive of liposarcoma 
MRI Left thigh showing mass infiltrating the femoral vessels 
 
 
 
 
 
 
 
 
 
Peroperative photograph showing anterior compartmental resection of soft tissue 
sarcoma right thigh  
 Muscle group excision - forearm 
 
 
 
 
 
 
 
 
 
Soft tissue sarcoma right thigh infiltrating superficial femoral vein 
 Vascular reconstruction of superficial femoral vein 
 
 
 
 
 
 
 
 
Rreconstruction  with skin graft after excision of recurrent sarcoma of right thigh 
Upper humeral resection in soft tissue sarcoma of right shoulder 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Latissmus dorsi flap reconstruction
